Auxilium Pharmaceuticals to Announce Third Quarter 2010 Results and Conduct Conference Call on Thursday, November 4, 2010

Oct 21, 2010, 07:00 ET from Auxilium Pharmaceuticals, Inc.

MALVERN, Pa., Oct. 21 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, will release results for the third quarter 2010 on Thursday, November 4, 2010 before the opening of the financial markets. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the third quarter 2010.  The presentation slides to be used during the call will be available on the "For Investors" section of the Auxilium web site under the "Presentations" tab beginning at 7 a.m. ET on Thursday, November 4, 2010.  A web cast of the conference call and the presentation slides will be available on the "For Investors" section of the Auxilium web site under the "Events" tab beginning at 10:00 a.m. ET on Thursday, November 4, 2010.  A question and answer session will follow the presentations.  

Mr. Armando Anido, Chief Executive Officer and President, will host the conference call.

Conference call details: Date: Time: Dial-in (U.S.): Dial-in (International): Web cast: Passcode:

Thursday, November 4, 2010 10:00 a.m. ET 866-788-0540 857-350-1678 http://ir.auxilium.com/ AUXILIUM

To access an audio replay of the call: Access number (U.S.): Access number (International): Replay Passcode #:

888-286-8010 617-801-6888 80874005

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists.  Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a topical testosterone gel, for the treatment of hypogonadism.  Auxilium has four projects in clinical development.  XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis).  Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) and its fentanyl pain product using its transmucosal delivery system are in phase I of development.  The Company is currently seeking a partner to further develop these product candidates.  Auxilium has rights to additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system.  Auxilium also has options to all indications using XIAFLEX for non-topical formulations.  For additional information, visit http://www.auxilium.com.

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the duration of any patent protection afforded the Company resulting from the Company's U.S. Patent No. 7,811,560 (the '560 patent);  the expiration of the '560 patent; the potential expansion of the '560 patent claims resulting from any of the Company's continuing patent applications; the potential for XIAFLEX to be used in multiple indications; and products in development for Frozen Shoulder syndrome, overactive bladder, pain, hormone replacement and urologic disease. All statements other than statements of historical facts contained in this release, including but not limited to, statements regarding future expectations, plans and prospects for the Company, statements regarding forward-looking financial information and other statements containing the words "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and similar expressions, as they relate to the Company, constitute forward-looking statements. Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, the performance of third-party service providers, decisions by regulatory authorities regarding whether or when to proceed to the next phase of clinical trials, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 under the heading "Risk Factors," and in Auxilium's Quarterly Report on Form 10-Q for the period ended June 30, 2010, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of the Company's home page on the Internet at http://www.auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial which could also cause actual results to differ from those contained in forward-looking statements. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide the Company's expectations, plans or forecasts of future events and views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this release.

Contacts: James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 jfickenscher@auxilium.com

William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 wsargent@auxilium.com

SOURCE Auxilium Pharmaceuticals, Inc.



RELATED LINKS

http://www.auxilium.com